Genedrive (GDR) RNS Announcements

Add to Alert list
Date Time Source Announcement
21 Nov 2022 07:00 AM
RNS
Audited Final Results
14 Nov 2022 07:00 AM
RNS
Notice of Results
24 Oct 2022 07:00 AM
RNS
Grant of options
05 Oct 2022 04:40 PM
RNS
Second Price Monitoring Extn
05 Oct 2022 04:35 PM
RNS
Price Monitoring Extension
05 Oct 2022 07:00 AM
RNS
US FDA pre-submission for Genedrive MT-RNR1 kit
26 Sep 2022 07:00 AM
RNS
NICE to accelerate evaluation of Genedrive test
22 Aug 2022 07:00 AM
RNS
NICE includes CYP2C19-ID Kit in new programme
05 Jul 2022 02:06 PM
RNS
Second Price Monitoring Extn
05 Jul 2022 02:00 PM
RNS
Price Monitoring Extension
16 Jun 2022 07:00 AM
RNS
NICE to evaluate the Genedrive® MT-RNR1 Test
30 May 2022 09:05 AM
RNS
Second Price Monitoring Extn
30 May 2022 09:00 AM
RNS
Price Monitoring Extension
30 May 2022 07:00 AM
RNS
Point-of-Care COV19-ID Kit receives CTDA approval
27 May 2022 07:00 AM
RNS
Block listing Interim Review
25 Apr 2022 09:05 AM
RNS
Second Price Monitoring Extn
25 Apr 2022 09:00 AM
RNS
Price Monitoring Extension
20 Apr 2022 02:00 PM
RNS
Price Monitoring Extension
08 Apr 2022 04:41 PM
RNS
Second Price Monitoring Extn
08 Apr 2022 04:35 PM
RNS
Price Monitoring Extension
04 Apr 2022 05:13 PM
RNS
Director/PDMR Shareholding
04 Apr 2022 11:05 AM
RNS
Second Price Monitoring Extn
04 Apr 2022 11:00 AM
RNS
Price Monitoring Extension
04 Apr 2022 09:05 AM
RNS
Second Price Monitoring Extn
04 Apr 2022 09:00 AM
RNS
Price Monitoring Extension
31 Mar 2022 09:05 AM
RNS
Second Price Monitoring Extn
31 Mar 2022 09:00 AM
RNS
Price Monitoring Extension
29 Mar 2022 11:06 AM
RNS
Second Price Monitoring Extn
29 Mar 2022 11:00 AM
RNS
Price Monitoring Extension
29 Mar 2022 10:00 AM
RNS
NICE issues Medtech Innovation Briefing
29 Mar 2022 07:00 AM
RNS
Half-year Report
25 Mar 2022 11:05 AM
RNS
Second Price Monitoring Extn
25 Mar 2022 11:00 AM
RNS
Price Monitoring Extension
24 Mar 2022 02:00 PM
RNS
Price Monitoring Extension
22 Mar 2022 04:41 PM
RNS
Second Price Monitoring Extn
22 Mar 2022 04:36 PM
RNS
Price Monitoring Extension
21 Mar 2022 03:16 PM
RNS
PALOH study results published in JAMA Pediatrics
21 Mar 2022 09:05 AM
RNS
Second Price Monitoring Extn
21 Mar 2022 09:00 AM
RNS
Price Monitoring Extension
18 Mar 2022 04:41 PM
RNS
Second Price Monitoring Extn
18 Mar 2022 04:36 PM
RNS
Price Monitoring Extension
18 Mar 2022 02:05 PM
RNS
Second Price Monitoring Extn
18 Mar 2022 02:00 PM
RNS
Price Monitoring Extension
18 Mar 2022 02:00 PM
RNS
First NHS Deployments of Genedrive System for AIHL
17 Mar 2022 07:00 AM
RNS
Board appointment
16 Mar 2022 04:41 PM
RNS
Second Price Monitoring Extn
16 Mar 2022 04:35 PM
RNS
Price Monitoring Extension
02 Mar 2022 07:00 AM
RNS
Further re Directorate Change
23 Feb 2022 05:00 PM
RNS
Director/PDMR Shareholding
23 Feb 2022 09:05 AM
RNS
Second Price Monitoring Extn

Genedrive plc is a medical equipment company based in Manchester, UK that develops and sells point-of-care molecular diagnostic platforms. Their products are used in healthcare settings, particularly in emergency medicine, for patient stratification and disease detection. Genedrive's goal is to improve clinical outcomes with easy-to-use tests. 

 Genedrive's major products include:
Genedrive CYP2C19 ID Kit: A rapid test that establishes metaboliser status in time-critical settings
Genedrive MT-RNR1 ID Kit: The world's first point-of-care genetic test to reduce the risk of aminoglycoside induced hearing loss

Genedrive was founded on contract research services for pharmaceutical and biotech companies, and was originally named Epistem Holdings Inc. when it was floated on the London AIM market in 2007. The company was renamed genedrive plc in 2016 to reflect its new focus on molecular diagnostics, and divested its contract research services divisions in 2018.

GDR share price launched at 129p in 2007. 

UK 100

Latest directors dealings